In COVID-19 clinical update #75, Daniel Griffin reviews vaccine effectiveness against transmission, modeling effectiveness of daily antigen tests, updated CDC guidance for fully vaccinated, risk of infection with time after mRNA vaccination, reduced risk of infection after vaccination, therapeutic anticoagulants in critically ill patients, and 6 month outcomes in hospitalized patients.
In COVID-19 clinical update #74, Daniel Griffin covers infections in vaccinated individuals, expansion of Regeneron monoclonal antibody cocktail for prophylaxis, neutralization of variants by antibodies produced by infection or vaccination, longer hospital stays associated with remdesivir treatment, and post-acute sequelae of infection and impact on quality of life 1-6 months after illness.
TWiV reviews a leaked CDC document on virulence and spread of the delta variant, and how anti-alphavirus antibodies that do not neutralize infection can nevertheless protect mice from disease.
Kiran joins TWiV to discuss the findings of a team at Columbia University Medical Center on COVID-19 neuropathology, and the conclusion that SARS-CoV-2 does not reproduce in the central nervous system.
In COVID-19 clinical update #73, Daniel Griffin reviews updated mask guidance from CDC, infections in public school district employees, effectiveness of vaccines against delta variant, antibody response after third vaccine dose in kidney transplant recipients, protection afforded by mRNA vaccines fully vaccinated people with and without prior infections, correlates of protection in nonhuman primates, lack of effectiveness of doxycycline, neurological manifestations of COVID-19, and infection in vaccinated health care workers.
TWiVsters review off-season epidemics of respiratory syncytial virus in Australia after easing of COVID-19 restrictions, and impaired innate immune responses in upper respiratory tract cells from patients with severe COVID-19.
In this special episode, Daniel Griffin answers listener questions on COVID-19 vaccines, vaccine misinformation, long COVID, masking and distancing, school safety, and much more.
In COVID-19 clinical update #72, Daniel Griffin covers long term symptoms in children, outcomes for MIS-C, recent guidance from the American Academy of Pediatrics, a large well traced outbreak of delta variant, low dose mRNA vaccination generates durable T cell memory and antibodies, protective immunity in recovered patients, assessment of BinaxNOW, no effect of oral azithromycin, post-discharge symptoms in Nigeria, and therapeutics for low and middle income countries.
The Team with Invincible Values discusses whether dogs or cats passively carry SARS-CoV-2 on hair and foot pads, maternal to fetal transfer of antibodies in infected or vaccinated pregnant women, and evidence that retroviruses infected cetaceans before and after they moved into the oceans.
In COVID-19 clinical update #71, Daniel Griffin reviews updated school and child care guidance from CDC, transmission in schools, accuracy of lateral flow assays, update to J&J/Janssen vaccine EUA to include GBS, interim immunogenicity of Ad.26.CoV2.s, effectiveness of mRNA vaccines to prevent hospitalization, Bamlanivimab plus Etesevimab for mild or moderate disease, and a meta-analysis of ivermectin results.